OBJECTIVE: Based on combined data for 4880 patients, 2 previous studies reported that advanced age is a predictor of increased renal cell carcinoma-specific mortality (RCC-SM). We explored the effect of age in cubic spline analyses to identify the age groups with the most elevated risk for renal cell carcinoma (RCC). METHODS: Our study included 3595 patients from 14 European centres who had partial or radical nephrectomies. We used the Kaplan-Meier method to compile life tables, and we performed Cox regression analyses to assess RCC-SM. Covariates included age at diagnosis, sex, TNM (tumour, node, metastasis) stage, tumour size, Fuhrman grade, symptom classification and histological subtype. RESULTS: Age ranged from 10 to 89 (mean 63, median 67) years. The median duration of follow-up was 2.9 years. The median survival for the cohort was 13.4 years. Stage distribution was as follows: 1915 patients (53.3%) had stage I disease, 388 (10.8%) had stage II, 895 (24.9%) had stage III and 397 (11.0%) had stage IV disease. In multivariate analyses, we coded age at diagnosis as a cubic spline, and it achieved independent predictor status (p < 0.001). The risk of RCC-SM was lowest among patients younger than 50 years. We observed an increase in RCC-SM until the age of 50, at which point the level of risk reached a plateau. We observed a second increase among patients aged 75-89 years. We found similar patterns when we stratified patients according to the 2002 American Joint Committee on Cancer (AJCC) stages. CONCLUSION: The effect of age shows prognostic significance and indicates that follow-up and possibly secondary treatments might need to be adjusted according to the age of the patient.
OBJECTIVE: Based on combined data for 4880 patients, 2 previous studies reported that advanced age is a predictor of increased renal cell carcinoma-specific mortality (RCC-SM). We explored the effect of age in cubic spline analyses to identify the age groups with the most elevated risk for renal cell carcinoma (RCC). METHODS: Our study included 3595 patients from 14 European centres who had partial or radical nephrectomies. We used the Kaplan-Meier method to compile life tables, and we performed Cox regression analyses to assess RCC-SM. Covariates included age at diagnosis, sex, TNM (tumour, node, metastasis) stage, tumour size, Fuhrman grade, symptom classification and histological subtype. RESULTS: Age ranged from 10 to 89 (mean 63, median 67) years. The median duration of follow-up was 2.9 years. The median survival for the cohort was 13.4 years. Stage distribution was as follows: 1915 patients (53.3%) had stage I disease, 388 (10.8%) had stage II, 895 (24.9%) had stage III and 397 (11.0%) had stage IV disease. In multivariate analyses, we coded age at diagnosis as a cubic spline, and it achieved independent predictor status (p < 0.001). The risk of RCC-SM was lowest among patients younger than 50 years. We observed an increase in RCC-SM until the age of 50, at which point the level of risk reached a plateau. We observed a second increase among patients aged 75-89 years. We found similar patterns when we stratified patients according to the 2002 American Joint Committee on Cancer (AJCC) stages. CONCLUSION: The effect of age shows prognostic significance and indicates that follow-up and possibly secondary treatments might need to be adjusted according to the age of the patient.
Authors: Edward M Messing; Judith Manola; George Wilding; Kathleen Propert; Jonathan Fleischmann; E David Crawford; J Edson Pontes; Richard Hahn; Donald Trump Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Joseph I Clark; Michael B Atkins; Walter J Urba; Steven Creech; Robert A Figlin; Janice P Dutcher; Larry Flaherty; Jeffrey A Sosman; Theodore F Logan; Richard White; Geoffrey R Weiss; Bruce G Redman; Christopher P G Tretter; David McDermott; John W Smith; Michael S Gordon; Kim A Margolin Journal: J Clin Oncol Date: 2003-06-16 Impact factor: 44.544
Authors: Ricardo F Sánchez-Ortiz; Charles J Rosser; Lydia T Madsen; David A Swanson; Christopher G Wood Journal: J Urol Date: 2004-06 Impact factor: 7.450
Authors: H Borgmann; M Musquera; A Haferkamp; A Vilaseca; T Klatte; S F Shariat; A Scavuzzo; M A Jimenez Rios; I Wolff; U Capitanio; P Dell'Oglio; L M Krabbe; E Herrmann; T Ecke; D Vergho; N Huck; N Wagener; S Pahernik; S Zastrow; M Wirth; C Surcel; C Mirvald; K Prochazkova; G Hutterer; R Zigeuner; L Cindolo; M Hora; C G Stief; M May; S D Brookman-May Journal: World J Urol Date: 2017-08-23 Impact factor: 4.226
Authors: G Procopio; J Bellmunt; J Dutcher; S Bracarda; J Knox; A Brueckner; I Molnar; B Escudier; T E Hutson Journal: Br J Cancer Date: 2013-01-15 Impact factor: 7.640
Authors: T E Hutson; R M Bukowski; B I Rini; M E Gore; J M Larkin; R A Figlin; C H Barrios; B Escudier; X Lin; K Fly; B Martell; E Matczak; R J Motzer Journal: Br J Cancer Date: 2014-01-16 Impact factor: 7.640